Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review

Journal of the American College of Cardiology

Volumn 73, Issue 8, 2019, Pages 948-963

  Stahl, Eric P ^a   Dhindsa, Devinder S ^b   Lee, Suegene K ^a   Sandesara, Pratik B ^b   Chalasani, Naga P ^c   Sperling, Laurence S ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY CLINIC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cardiovascular disease; metabolic syndrome; nonalcoholic fatty liver disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; CENICRIVIROC; ELAFIBRANOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LOSARTAN; METFORMIN; OBETICHOLIC ACID; PIOGLITAZONE; PITAVASTATIN; PLACEBO; ROSUVASTATIN; SIMVASTATIN;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BARIATRIC SURGERY; BODY WEIGHT LOSS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DRUG MECHANISM; DYSLIPIDEMIA; FATTY LIVER; FRAMINGHAM RISK SCORE; HEART ARRHYTHMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FAILURE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; COMPLICATION; GLOBAL HEALTH; METABOLISM; MORBIDITY; RISK FACTOR;

CARDIOVASCULAR DISEASES; GLOBAL HEALTH; HUMANS; MORBIDITY; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; RISK FACTORS;

EID: 85061541118     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.11.050     Document Type: Review

References (169)

1. Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
2. Masuoka, H.C., Chalasani, N., Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281 (2013), 106–122.
3. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67 (2018), 328–357.
4. Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L., Wymer, M., Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 (2016), 73–84.
5. Younossi, Z., Anstee, Q.M., Marietti, M., et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15 (2018), 11–20.
6. Le, M.H., Devaki, P., Ha, N.B., et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One, 12, 2017, e0173499.
7. Lazo, M., Hernaez, R., Eberhardt, M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 178 (2013), 38–45.
8. Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
9. Wong, R.J., Aguilar, M., Cheung, R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
10. Adams, L.A., Anstee, Q.M., Tilg, H., Targher, G., Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66 (2017), 1138–1153.
11. Kotronen, A., Yki-Jarvinen, H., Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28 (2008), 27–38.
12. Sperling, L.S., Mechanick, J.I., Neeland, I.J., et al. The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. J Am Coll Cardiol 66 (2015), 1050–1067.
13. Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., Zhang, Z., Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Scientific Reports, 6, 2016, 33386.
14. Kaswala, D.H., Lai, M., Afdhal, N.H., Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016. Dig Dis Sci 61 (2016), 1356–1364.
15. Corey, K.E., Klebanoff, M.J., Tramontano, A.C., Chung, R.T., Hur, C., Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 61 (2016), 2108–2117.
16. European Association for the Study of the Liver European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 (2016), 1388–1402.
17. Francque, S.M., van der Graaff, D., Kwanten, W.J., Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. J Hepatol 65 (2016), 425–443.
18. Deanfield, J.E., Halcox, J.P., Rabelink, T.J., Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007), 1285–1295.
19. Kasumov, T., Edmison, J.M., Dasarathy, S., Bennett, C., Lopez, R., Kalhan, S.C., Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism 60 (2011), 776–781.
20. Pacana, T., Cazanave, S., Verdianelli, A., et al. Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease. PLoS One, 10, 2015, e0136822.
21. Cusi, K., Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142 (2012), 711–725.e6.
22. Villanova, N., Moscatiello, S., Ramilli, S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42 (2005), 473–480.
23. Neuschwander-Tetri, B.A., Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 52 (2010), 774–788.
24. DeFilippis, A.P., Blaha, M.J., Martin, S.S., et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 227 (2013), 429–436.
25. Siddiqui, M.S., Fuchs, M., Idowu, M.O., et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol 13 (2015), 1000–1008.e3.
26. Sonmez, A., Nikolic, D., Dogru, T., et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol 9 (2015), 576–582.
27. Mannisto, V.T., Simonen, M., Soininen, P., et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res 55 (2014), 2676–2684.
28. Corey, K.E., Misdraji, J., Gelrud, L., Zheng, H., Chung, R.T., Krauss, R.M., Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis, 13, 2014, 100.
29. Ma, J., Hwang, S.J., Pedley, A., et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol 66 (2017), 390–397.
30. Fraser, A., Harris, R., Sattar, N., Ebrahim, S., Davey Smith, G., Lawlor, D.A., Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32 (2009), 741–750.
31. Mantovani, A., Byrne, C.D., Bonora, E., Targher, G., Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care 41 (2018), 372–382.
32. Lim, S., Oh, T.J., Koh, K.K., Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 201 (2015), 408–414.
33. Birkenfeld, A.L., Shulman, G.I., Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59 (2014), 713–723.
34. Leamy, A.K., Egnatchik, R.A., Young, J.D., Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 52 (2013), 165–174.
35. Targher, G., Bertolini, L., Padovani, R., et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabetic Med 23 (2006), 403–409.
36. Hamaguchi, M., Kojima, T., Takeda, N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13 (2007), 1579–1584.
37. Haring, R., Wallaschofski, H., Nauck, M., Dorr, M., Baumeister, S.E., Volzke, H., Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 50 (2009), 1403–1411.
38. Zhou, Y.J., Li, Y.Y., Nie, Y.Q., Huang, C.M., Cao, C.Y., Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 13 (2012), 153–160.
39. Treeprasertsuk, S., Leverage, S., Adams, L.A., Lindor, K.D., St Sauver, J., Angulo, P., The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 32 (2012), 945–950.
40. Pisto, P., Santaniemi, M., Bloigu, R., Ukkola, O., Kesaniemi, Y.A., Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 4, 2014, e004973.
41. Jepsen, P., Vilstrup, H., Mellemkjaer, L., et al. Prognosis of patients with a diagnosis of fatty liver–a registry-based cohort study. Hepato-Gastroenterology 50 (2003), 2101–2104.
42. Pickhardt, P.J., Hahn, L., Munoz del Rio, A., Park, S.H., Reeder, S.B., Said, A., Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. Am J Roentgenology 202 (2014), 752–758.
43. Targher, G., Bertolini, L., Padovani, R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007), 1212–1218.
44. Gill, R.M., Belt, P., Wilson, L., Bass, N.M., Ferrell, L.D., Centrizonal arteries and microvessels in nonalcoholic steatohepatitis. Am J Surg Pathol 35 (2011), 1400–1404.
45. Coulon, S., Francque, S., Colle, I., et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59 (2012), 442–449.
46. Yilmaz, Y., Yonal, O., Kurt, R., et al. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch Med Res 42 (2011), 38–43.
47. Yla-Herttuala, S., Rissanen, T.T., Vajanto, I., Hartikainen, J., Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49 (2007), 1015–1026.
48. Tripodi, A., Fracanzani, A.L., Primignani, M., et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol 61 (2014), 148–154.
49. Abu-Shanab, A., Quigley, E.M., The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 7 (2010), 691–701.
50. Brown, J.M., Hazen, S.L., The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med 66 (2015), 343–359.
51. Lonardo, A., Sookoian, S., Pirola, C.J., Targher, G., Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 65 (2016), 1136–1150.
52. Smagris, E., BasuRay, S., Li, J., et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61 (2015), 108–118.
53. Petta, S., Valenti, L., Marchesini, G., et al. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One, 8, 2013, e74089.
54. Palmer, C.N., Maglio, C., Pirazzi, C., et al. Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One, 7, 2012, e39362.
55. Lauridsen, B.K., Stender, S., Kristensen, T.S., et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. European Heart Journal 39 (2018), 385–393.
56. Kozlitina, J., Smagris, E., Stender, S., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46 (2014), 352–356.
57. Dongiovanni, P., Petta, S., Maglio, C., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61 (2015), 506–514.
58. Francque, S., Laleman, W., Verbeke, L., et al. Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture. Lab Invest 92 (2012), 1428–1439.
59. VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62 (2015), 773–783.
60. Hallsworth, K., Hollingsworth, K.G., Thoma, C., et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58 (2013), 757–762.
61. Matteoni, C.A., Younossi, Z.M., Gramlich, T., Boparai, N., Liu, Y.C., McCullough, A.J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
62. Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
63. Soderberg, C., Stal, P., Askling, J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51 (2010), 595–602.
64. Zeb, I., Li, D., Budoff, M.J., et al. Nonalcoholic fatty liver disease and incident cardiac events: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 67 (2016), 1965–1966.
65. Allen, A.M., Therneau, T.M., Larson, J.J., Coward, A., Somers, V.K., Kamath, P.S., Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology 67 (2018), 1726–1736.
66. Ekstedt, M., Hagstrom, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
67. Targher, G., Bertolini, L., Rodella, S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30 (2007), 2119–2121.
68. Dunn, W., Xu, R., Wingard, D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 103 (2008), 2263–2271.
69. Ong, J.P., Pitts, A., Younossi, Z.M., Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 49 (2008), 608–612.
70. Lazo, M., Hernaez, R., Bonekamp, S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
71. Kim, D., Kim, W.R., Kim, H.J., Therneau, T.M., Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
72. Fraser, A., Harris, R., Sattar, N., Ebrahim, S., Smith, G.D., Lawlor, D.A., Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 27 (2007), 2729–2735.
73. Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G., Barbui, C., Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65 (2016), 589–600.
74. Mahfood Haddad, T., Hamdeh, S., Kanmanthareddy, A., Alla, V.M., Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis. Diabetes Metab Syndr 11 Suppl 1 (2017), S209–S216.
75. Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., Zhang, Z., Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep, 6, 2016, 33386.
76. Guo, K., Zhang, L., Lu, J., et al. Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes. J Diabetes Complications 31 (2017), 80–85.
77. Kang, J.H., Cho, K.I., Kim, S.M., et al. Relationship between nonalcoholic fatty liver disease and carotid artery atherosclerosis beyond metabolic disorders in non-diabetic patients. J Cardiovasc Ultrasound 20 (2012), 126–133.
78. Kim, D., Choi, S.Y., Park, E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56 (2012), 605–613.
79. Kim, J., Lee, D.Y., Park, S.E., et al. Increased risk for development of coronary artery calcification in subjects with non-alcoholic fatty liver disease and systemic inflammation. PLoS One, 12, 2017, e0180118.
80. Park, H.E., Kwak, M.S., Kim, D., Kim, M.K., Cha, M.J., Choi, S.Y., Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study. J Clin Endocrinol Metab 101 (2016), 3134–3143.
81. Sinn, D.H., Kang, D., Chang, Y., et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 66 (2017), 323–329.
82. Sung, K.C., Wild, S.H., Kwag, H.J., Byrne, C.D., Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 35 (2012), 2359–2364.
83. Wu, R., Hou, F., Wang, X., et al. Nonalcoholic fatty liver disease and coronary artery calcification in a northern chinese population: a cross sectional study. Sci Rep, 7, 2017, 9933.
84. Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
85. Sookoian, S., Pirola, C.J., Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 49 (2008), 600–607.
86. Jaruvongvanich, V., Wirunsawanya, K., Sanguankeo, A., Upala, S., Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis. Dig Liver Dis 48 (2016), 1410–1417.
87. Zhou, Y.Y., Zhou, X.D., Wu, S.J., et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatology Communications 2 (2018), 376–392.
88. Sinn, D.H., Cho, S.J., Gu, S., et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. Gastroenterology 151 (2016), 481–488.e1.
89. Wong, V.W., Wong, G.L., Yeung, J.C., et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology 63 (2016), 754–763.
90. Ishiba, H., Sumida, Y., Kataoka, S., et al. Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 46 (2016), 1107–1117.
91. Puchner, S.B., Lu, M.T., Mayrhofer, T., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 274 (2015), 693–701.
92. Keskin, M., Hayiroglu, M.I., Uzun, A.O., Guvenc, T.S., Sahin, S., Kozan, O., Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol 120 (2017), 1720–1726.
93. Emre, A., Terzi, S., Celiker, E., et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 116 (2015), 1810–1814.
94. Trovato, F.M., Martines, G.F., Catalano, D., Musumeci, G., Pirri, C., Trovato, G.M., Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol 221 (2016), 275–279.
95. Markus, M.R., Baumeister, S.E., Stritzke, J., et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol 33 (2013), 1690–1695.
96. Bonapace, S., Valbusa, F., Bertolini, L., et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One, 9, 2014, e88371.
97. Mantovani, A., Pernigo, M., Bergamini, C., et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64 (2015), 879–887.
98. Fracanzani, A.L., Pisano, G., Consonni, D., et al. Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease. PLoS One, 11, 2016, e0162473.
99. Kim, B.J., Cheong, E.S., Kang, J.G., Kim, B.S., Kang, J.H., Relationship of epicardial fat thickness and nonalcoholic fatty liver disease to coronary artery calcification: from the CAESAR study. J Clin Lipidol 10 (2016), 619–626.e1.
100. Mantovani, A., Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis. J Clin Transl Hepatol 5 (2017), 134–141.
101. Sinner, M.F., Wang, N., Fox, C.S., et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111 (2013), 219–224.
102. Targher, G., Mantovani, A., Pichiri, I., et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 125 (2013), 301–309.
103. Targher, G., Valbusa, F., Bonapace, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One, 8, 2013, e57183.
104. Käräjämäki, A.J., Patsi, O.P., Savolainen, M., Kesaniemi, Y.A., Huikuri, H., Ukkola, O., Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One, 10, 2015, e0142937.
105. Hung, C.S., Tseng, P.H., Tu, C.H., et al. Nonalcoholic fatty liver disease is associated with qt prolongation in the general population. J Am Heart Assoc, 4, 2015.
106. Mantovani, A., Rigamonti, A., Bonapace, S., et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care 39 (2016), 1416–1423.
107. Anstee, Q.M., Mantovani, A., Tilg, H., Targher, G., Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 15 (2018), 425–439.
108. Long, M.T., Yin, X., Larson, M.G., et al. Relations of liver fat with prevalent and incident atrial fibrillation in the framingham heart study. J Am Heart Assoc, 6, 2017.
109. Kumar, M.S., Singh, A., Jaryal, A.K., et al. Cardiovascular autonomic dysfunction in patients of nonalcoholic fatty liver disease. Int J Hepatol, 2016, 2016, 5160754.
110. Eckel, R.H., Jakicic, J.M., Ard, J.D., et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25 Pt B (2014), 2960–2984.
111. Oni, E.T., Kalathiya, R., Aneni, E.C., et al. Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk. Am J Cardiol 115 (2015), 34–39.
112. Dogan, S., Celikbilek, M., Yilmaz, Y.K., et al. Association between liver fibrosis and coronary heart disease risk in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 27 (2015), 298–304.
113. Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2015), 367–378.e5 quiz e14–5.
114. Chang, Y., Cho, Y.K., Kim, Y., et al. Non-heavy drinking and worsening of non-invasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology 69 (2019), 64–75.
115. Ajmera, V., Belt, P., Wilson, L.A., et al. Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol 16 (2018), 1511–1520.e5.
116. Costanzo, S., Di Castelnuovo, A., Donati, M.B., Iacoviello, L., de Gaetano, G., Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol 55 (2010), 1339–1347.
117. Bader, T., The myth of statin-induced hepatotoxicity. Am J Gastroenterol 105 (2010), 978–980.
118. Chalasani, N., Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 41 (2005), 690–695.
119. Del Ben, M., Baratta, F., Polimeni, L., et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 27 (2017), 161–167.
120. Bjornsson, E., Jacobsen, E.I., Kalaitzakis, E., Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 56 (2012), 374–380.
121. Cohen, D.E., Anania, F.A., Chalasani, N., An assessment of statin safety by hepatologists. Am J Cardiol 97 (2006), 77c–81c.
122. Downs, J.R., Clearfield, M., Weis, S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998), 1615–1622.
123. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994), 1383–1389.
124. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002), 7–22.
125. Kashani, A., Phillips, C.O., Foody, J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114 (2006), 2788–2797.
126. Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M.D., Hall, S.D., Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 126 (2004), 1287–1292.
127. Catapano, A.L., Graham, I., De Backer, G., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37 (2016), 2999–3058.
128. Bays, H., Cohen, D.E., Chalasani, N., Harrison, S.A., The National Lipid Association's Statin Safety Task F. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S47–S57.
129. Hyogo, H., Ikegami, T., Tokushige, K., et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res 41 (2011), 1057–1065.
130. Kargiotis, K., Athyros, V.G., Giouleme, O., et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 21 (2015), 7860–7868.
131. Nascimbeni, F., Aron-Wisnewsky, J., Pais, R., et al. Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterol, 3, 2016, e000075.
132. Riley, P., Al Bakir, M., O'Donohue, J., Crook, M., Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk. Cardiovasc Ther 27 (2009), 216–220.
133. Athyros, V.G., Tziomalos, K., Gossios, T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376 (2010), 1916–1922.
134. Tikkanen, M.J., Fayyad, R., Faergeman, O., et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 168 (2013), 3846–3852.
135. Athyros, V.G., Giouleme, O., Ganotakis, E.S., et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 7 (2011), 796–805.
136. Stone, N.J., Robinson, J.G., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63:25 Pt B (2014), 2889–2934.
137. Shen, H., Shahzad, G., Jawairia, M., Bostick, R.M., Mustacchia, P., Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 40 (2014), 1066–1073.
138. Meythaler, J.M., Varma, R.R., Reye's syndrome in adults: diagnostic considerations. Archives of internal medicine 147 (1987), 61–64.
139. Pappachan, J.M., Antonio, F.A., Edavalath, M., Mukherjee, A., Non-alcoholic fatty liver disease: a diabetologist's perspective. Endocrine 45 (2014), 344–353.
140. Rouabhia, S., Milic, N., Abenavoli, L., Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism. Expert Rev Gastroenterol Hepatol 8 (2014), 343–349.
141. Lavine, J.E., Schwimmer, J.B., Van Natta, M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305 (2011), 1659–1668.
142. Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
143. Erdmann, E., Dormandy, J.A., Charbonnel, B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 (2007), 1772–1780.
144. Liao, H.W., Saver, J.L., Wu, Y.L., Chen, T.H., Lee, M., Ovbiagele, B., Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open, 7, 2017, e013927.
145. Belfort, R., Harrison, S.A., Brown, K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
146. Cusi, K., Orsak, B., Bril, F., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165 (2016), 305–315.
147. Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362 (2010), 1675–1685.
148. Musso, G., Cassader, M., Paschetta, E., Gambino, R., Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177 (2017), 633–640.
149. Said, A., Akhter, A., Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis. Ann Hepatol 16 (2017), 538–547.
150. Dormandy, J., Bhattacharya, M., van Troostenburg de Bruyn, A.R., for the PROactive Investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 32 (2009), 187–202.
151. Armstrong, M.J., Gaunt, P., Aithal, G.P., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
152. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
153. Vorsanger, M.H., Subramanyam, P., Weintraub, H.S., et al. Cardiovascular effects of the new weight loss agents. J Am Coll Cardiol 68 (2016), 849–859.
154. Yokohama, S., Yoneda, M., Haneda, M., et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40 (2004), 1222–1225.
155. Georgescu, E.F., Ionescu, R., Niculescu, M., Mogoanta, L., Vancica, L., Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 15 (2009), 942–954.
156. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., Sleight, P., for the Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342 (2000), 154–160.
157. Lonn, E., Bosch, J., Yusuf, S., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (2005), 1338–1347.
158. Sesso, H.D., Buring, J.E., Christen, W.G., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 300 (2008), 2123–2133.
159. Bower, G., Toma, T., Harling, L., et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg 25 (2015), 2280–2289.
160. Lassailly, G., Caiazzo, R., Buob, D., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149 (2015), 379–388 quiz e15–6.
161. Vest, A.R., Heneghan, H.M., Agarwal, S., Schauer, P.R., Young, J.B., Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98 (2012), 1763–1777.
162. Pareek, M., Schauer, P.R., Kaplan, L.M., Leiter, L.A., Rubino, F., Bhatt, D.L., Metabolic surgery: weight loss, diabetes, and beyond. J Am Coll Cardiol 71 (2018), 670–687.
163. Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
164. Hameed, B., Terrault, N.A., Gill, R.M., et al. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 47 (2018), 645–656.
165. Ratziu, V., Harrison, S.A., Francque, S., et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology 150 (2016), 1147–1159.e5.
166. Sumida, Y., Yoneda, M., Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol 53 (2018), 362–376.
167. Friedman, S.L., Ratziu, V., Harrison, S.A., et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology 67 (2018), 1754–1767.
168. Ratziu, V., Sanyal, A., Francque, S., et al. Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR Study (abstr). J Hepatol 68 Suppl 1 (2018), S1–S2.
169. Lonardo, A., Nascimbeni, F., Mantovani, A., Targher, G., Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. J Hepatol 68 (2018), 335–352.